GREB1 tissue expression is associated with organ-confined prostate cancer
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
SOUSA-CANAVEZ, Juliana M.
CAMARA-LOPES, Luiz H.
Citação
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.30, n.1, p.16-20, 2012
Resumo
Objective: By reason of its heterogeneous behavior, it is difficult to determine the prognosis of many prostate cancer cases. Patients with the same clinicopathologic conditions may present varying clinical findings and rates of progression. We determined the role of new genes as potential molecular markers for prostate cancer prognosis. Materials and methods: We performed a microarray analysis of two pools of patients with prostate cancer divided according to their clinicopathologic characteristics. After that, we validated these results by testing the genes with most different expressions between the two pools using the quantitative real time polymerase chain reaction method. We analyzed gene expression in 33 patients with localized prostate cancer according to prostate specific antigen (PSA), pathologic stage, Gleason score, and biochemical recurrence. For statistical analysis we used the Mann-Whitney Test. Results: The microarray analysis revealed that 4,147 genes presented a different expression between the two pools. Among them, 3 genes, TMEFF2, GREB1, and THIL,, were at least 13-times overexpressed, and 1 gene, IGH3, which was at least 5times under-expressed in pool 1 (good prognosis) compared with pool 2 (bad prognosis), were selected for analysis. After the validation tests, GREB1 was significantly more overexpressed among patients with stage T2 compared with T3 (P = 0.020). The expressions of other 3 genes did not present significant differences according to the clinicopatholoOcal variables. Conclusions: Tissue expression of GREB1 is associated with organ-confined prostate cancer and may constitute a gene associated with a favorable prognosis.
Palavras-chave
Prostate, Prostate neoplasms, Biopsy, Prognosis, Gene expression, GREB1
Referências
- ABDUL M, 1995, UROL RES, V23, P185
- CARTER HB, 1990, J UROLOGY, V143, P742
- EPSTEIN JI, 2005, SCAND J UROL NEPHR S, V216, P34, DOI 10.1080/03008880510030932
- Gery S, 2002, ONCOGENE, V21, P4739, DOI 10.1038/sj.onc.1205142
- Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7
- Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
- Kattan MW, 1997, CANCER, V79, P528, DOI 10.1002/(SICI)1097-0142(19970201)79:3<528::AID-CNCR15>3.0.CO;2-5
- Liu WC, 2004, J BIOL CHEM, V279, P10167, DOI 10.1074/jbc.M307994200
- Nelson Peter S, 2004, J Urol, V172, pS28, DOI 10.1097/01.ju.0000142067.17181.68
- Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445
- PARTIN AW, 1993, J UROLOGY, V150, P110
- Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403
- Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4
- Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2
- STEMMERMANN GN, 1992, CANCER EPIDEM BIOMAR, V1, P189